Introduction {#Sec1}
============

Hereditary haemorrhagic telangiectasia (HHT) is a dominantly inherited genetic vascular disorder characterised by recurrent epistaxis, cutaneous telangiectasia, and visceral arteriovenous malformations \[[@CR1]\]. Clinical diagnosis is based on the Curaçao Criteria defined in 2000 by the Scientific Advisory Board of the HHT Foundation International Inc.; these consist of the following 4 signs: 1. epistaxis that occurs spontaneously on more than 1 occasion; 2. telangiectasias at characteristic sites including the nose, fingers, and oral cavity; 3. visceral lesions such as pulmonary, hepatic, or cerebral arteriovenous malformations (AVMs); 4. a family history of HHT (first-degree relative diagnosed with HHT via the same criteria). To be diagnosed with HHT, a patient must meet at least 3 of the 4 criteria \[[@CR1], [@CR2]\]. HHT is caused by mutations in *ENG* (encoding endoglin) \[[@CR3]\], *ACVRL1* (encoding activin receptor-like kinase 1) \[[@CR4]\], or *MADH4* (encoding SMAD4), which are responsible for an imbalanced state between anti- and pro-angiogenic factors, such as vascular endothelial growth factor (VEGF) \[[@CR5]\]. More than 90% of all cases of HHT are due to mutations in either *ENG* or *ACVRL1*.

Pregnancy, via the associated hormonal changes, promotes modification of the vascular bed and can have an impact on the disease \[[@CR6]\]. This corresponds to systemic vasodilatation and a progressive decrease in peripheral vascular resistance until the middle of the second trimester, before beginning to increase late in the third trimester. There is also an increase in cardiac output; the greatest increase, of up to 45% from baseline, occurs during the first trimester. The increase in cardiac output slows late in the second trimester and drops slightly late in the third trimester \[[@CR6]\]. The haemodynamic changes of pregnancy thus exacerbate blood shunting through already abnormal vascular beds \[[@CR7]\].

In HHT, complications during pregnancy are rare but can be severe. Screening for pulmonary AVMs is recommended in all cases before pregnancy, as well as pulmonary AVM (PAVM) embolotherapy if possible \[[@CR8]\]. However, symptoms may reach clinical thresholds for the first time during pregnancy or after delivery due to PAVMs.

Search strategy {#Sec2}
===============

We performed a literature search using the PubMed/MEDLINE and Scopus databases between March and April 2019 to identify all original articles evaluating or reporting complications during pregnancy in women with HHT. The search strategy was based on a combination of key words and controlled vocabulary for HHT and pregnancy such as "Hereditary Haemorrhagic Telangiectasia" or "Osler-Weber-Rendu disease" or "Osler-Weber-Rendu syndrome" and "pregnancy" or "pregnant woman" or pregnancy outcomes". No date or language limits were used.

Studies were excluded if they were not in English or French or if they did not present data about HHT and pregnancy. Articles were double screened by two reviewers (SDG & LD) based on title and abstract to determine whether they met the inclusion criteria for a full-text review. Articles without abstracts that appeared potentially relevant based on their title were kept for further consideration. Full text screening was completed by all authors.

Data and collection process: data regarding the number of patients and pregnancies, date of events (in gestational week), clinical presentation and treatments, term of delivery, obstetric events, route of delivery, and maternal and foetal outcome were extracted.

Results {#Sec4}
=======

Study selection and characteristics {#Sec5}
-----------------------------------

A total of 104 studies were identified after screening the title and abstract, 50 records were retained and underwent a full text examination, and 34 articles were included in the review (5 case series, 31 case reports; Fig. [1](#Fig1){ref-type="fig"}), representing a total of 630 women with HHT and 1577 pregnancies. The characteristics of the 5 case series are summarized in Table [1](#Tab1){ref-type="table"}, and those of the 31 case reports in Table [2](#Tab2){ref-type="table"}. Fig. 1Study selection flow chart for final inclusion in analysis. \* 2 case-report in the same article (*n* = 2) Table 1Characteristics of pregnancies in women with HHT: A summary of 5 case series published between 1967 and 2014Study\
(Author, type)Women (n) / Pregnancies (n)Live births (n)ResultsDeath\
n (% of pregnancies)Known diagnosis (%) / rate of patients screened for PAVM / CAVMObstetrics eventsRoute of delivery\
V D (%) / C S (%)Goodman et al. 1967Retrospective40 / 97+  80/213 controls78no statistically significant difference between the 2 groups (HHT and control)NA100 / - / -Miscarriage 14.4 vs 10%Abnormal outcome 50 vs 42%Prematurity 9.4 vs 10.3%Stillbirth 3.1 vs 2.6%NAShovlin et al. 1995Retrospective47/161NA11 severe events (6.8% of pregnancies)PAVM shunt deterioration *n* = 6Cerebro vascular accident *n* = 3Fatal Pulmonary hemorrhage *n* = 210/11 events in the « PAVM + » group3 (1.9)100 / - / -No Significant differencein the Miscarriage rate between the « PAVM + » and « PAVM -- » groupNAShovlin et al. 2008Prospective+retrospective199/484NA13 severe events (2.7% of pregnancies)Myocardial infarction *n* = 1 (died)Cerebro vascular accident *n* = 6(2 died / 2 ischaemic, 3 haemorrhagic, 1 NA)Pulmonary hemorrhage *n* = 6(2 died)5 (1)26 / - / -NAWain et al. 2012Retrospective226/560457NANA100 / - / -T1 Miscarriage 14.3%Preeclampsia 0.6%PPH 6.2%Prematurity 13.8% LBW 10.7%73.5 / 20.6De Gussem et al. 2014Retrospective87 / 24418515 severe events (6.1% of pregnancies)Heart failure *n* = 1Hemothorax *n* = 4(4 undiagnosed PAVMS)Hemoptysis *n* = 2Transient Ischaemic attack *n* = 2Post partum: Deep veinous thrombosis *n* = 1Pulmonary embolism *n* = 1Myocardial ischemia *n* = 2Intracranial hemorrhage *n* = 1Hemothorax *n* = 1NA100 / 13 / 17Miscarriage 20%Gestational hypertension 2.7%Preeclampsia 7%Eclampsia 0.5%Diabetes 3.2%PPH 2%Prematurity 12%70 / 30Total599 / 1546720Legends: *VD* Vaginal delivery*, CS* Cesarean section*, PAVM* Pulmonary arteriovenous malformation*, CAVM* Cerebral arteriovenous malformation*, LB* Live birth, *PP* Post partum, *PPH* Post partum hemorrhage, *LBW* Low-birth weight, NA Data Not Available Table 2Severe complications occurring during pregnancy or post-partum in women with HHT and published as case report (*n* = 31)ComplicationStudyTreatment\
T: Transfusion\
S: Surgery\
E: Embolisation\
D: DrainDate of events (wg)Clinical presentationTerm of delivey (wg)Maternal outcomeFœtal outcomeHaemothoraxTexier et al. 2018T + S/HHT--26Chest pain40GoodLive infantMd Noh et al. 2018E/HHT--20Dyspnea20Small bowel active hemorrhageFoetal deathRaiya et al. 2017D + E/HHT--23Dyspnea, chest pain40GoodLive infantJakobi et al. 2001S/HHT+26Severe hypoxemia40Hypoxemia PP embolisationSGA infantAdegboyega et al. 1996D/HHT--29Dyspnea Chest pain40Discharged no sequelaeLive infant (CS)Freixinet et al. 1995D + S/HHT?27Dyspnea?Severe mitral regurgitationLive infantBevelaqua et al. 1992D + E/HHT--26Dyspnea Chest pain40Diagnosed 6 wkLive infantLaroche et al. 1992D + S / HHT +29Dyspnea Chest pain37Post embolotherapyLive infantGammon et al. 1990D + E / HHT -24Dyspnea Chest pain30Heart failure resolvedLive infantWaring et al. 1990D + E/HHT +26Dyspnea32Heart failure resolvedLive infantHemoptysisBanerjee et al. 201834Hemoptysis--Good--Tandon et al. 2017reE of PAVM/HHT+32Unconscious and hypoxia37GoodLive infant (VD)Yaniv-Salem et al. 2017reE of PAVM/HHT+35Massive hemoptysis37GoodLive infant (VD)Wispelaere et al. 1996−/HHT+10Hemoptysis, transient loss of consciousness and tachycardiaTherapeutic abortionWell, required resection of PAVM--Severe HypoxemiaWorda et al. 2007−/HHT+12Dyspnea, cyanosis32Clinically improvedLive infant (CS)Jakobi et al. 2001−/HHT+25Hypoxemia IUGR25--Foetal deathSwinburne et al. 1986−/HHT+35Dyspnea, cyanosis35Post partum PAVM surgeryActive limited liveLive infant (CS)Cerebral Ischemic strokeSwietlik et al. 2008Craniotom/HHT+35Headache and dyspneaBrain abscess + PAVM35Post partum Hemothorax requiringre EmbolisationLive infant (CS)Intracranial hemorrhageGillard et al. 1996CAVM surgery/HHT--21Right hemiplegia, aphasia38.5Post partum epilepsy, Right hemiparesisLive infant (CS)Neau et al. 1988Brain surgery/HHT--30Right hemiplegia with aphasia violent headache and vomiting30Fatal (multiple CAVM, 5 hematomas)Foetal death (VD)Pulmonary edemaEuser et al. 2012HHT+33Pre-eclampsia, extensive edema in her legs and face34GoodLive infant (CS)High output heart failure all related to liver AVMBerthelot et al. 2015Diuretics/HHT--25Dyspnea33At day 16 post partum complete regression of congestive signsLive infant (CS)Lai et al. 2010?/HHT+36Rest Dyspnea36GoodLive infant (CS)Goussous et al. 2009?/HHT-29Right sided heart failure and preterm laborOn post partum day 2: dyspnea and lower extremity edema? (CS)Livneh et al. 1988Diuretics/HHT+26Weakness, dyspnea35 (?)At 4 months Post partum GoodLive infantLivneh et al. 1988Diuretics/HHT--26Dyspnea40At 4 months Post partum no more heart failureLive infantHepatobiliarynecrosisMcInroy et al. 1998Post partum Liver transplantation HHT+30Abdominal pain + fever30Biliary necrosis, liver transplant postpartumLive infantBauer et al. 1995Liver transplant HHT----Abdominal pain dyspnea, Melaena--Liver transplant--Gastrointestinal bleedingHillert et al. 2001Liver transplantation/HHT+27Diffuse abdominal paincholangitis29GoodLive infant (CS)Branch retinal artery occlusionAskim et al. 2017Subcutaneous Heparin +PAVM embolization/HHT--12Sudden painless scotoma in left eye40GoodLive infant (VD)Massive intraperitoneal haemorrhageSivarani et al. 2010HHT+36High-output cardiac failure36Fatal (on post-partum: massive haemorrhage in the intra-peritoneal cavity with multiple AVMs in the gastrointestinal tract)Live infant (CS)Legends: HHT- means that the diagnosis was not done before the complication and HHT+ means that the diagnosis was known before the complication. *CS* Cesarean section, *PAVM* Pulmonary arteriovenous malformation, *SGA* Small for gestational age*, VD* Vaginal delivery

Case series {#Sec6}
-----------

The 5 case series corresponded to a total of 1546 pregnancies in 599 HHT-affected women and 720 live births (unknown information in 2 series) \[[@CR8]--[@CR12]\]. The HHT diagnosis was known before the pregnancy in 4 series \[[@CR8]\], and all five studies were retrospective although one study \[[@CR8]\] had a prospective component. Severe events occurred in 2.7, 6.1 and 6.8% of pregnancies as summarized in Table [1](#Tab1){ref-type="table"}. Two case series reported maternal death during pregnancy \[[@CR8], [@CR10]\]; there was a total of 8 deaths in 645 pregnancies in 246 women (1.2% of pregnancies and 3.3% of affected women). PAVM-related complications (hypoxaemia and/or haemorrhage and/or ischaemic stroke) were the most frequent severe event described in HHT women during pregnancy, with a total of 26 events related to PAVM. Furthermore, out of 6 pulmonary haemorrhages published by Shovlin et al. \[[@CR8]\], four women had previous PAVM screening and embolisation. Cerebral AVM (CAVM)-related complications (intracranial haemorrhage) were observed in 4 cases and other complications (myocardial infarction, heart failure, deep venous thrombosis) in 7 cases \[[@CR8], [@CR10], [@CR12]\] (Table [1](#Tab1){ref-type="table"}).

Case reports {#Sec7}
------------

A total of 31 case reports of patients with HHT and life threatening events occurring during pregnancies were identified from the literature available. Mean gestational time at the presentation of the adverse events was 27 weeks of pregnancy (range: 20--36). Most complications appeared at the end of the second trimester or at the beginning of the third trimester of pregnancy.

Two maternal deaths and 2 foetal deaths occurred in 31 pregnancies in this series of case reports \[[@CR13], [@CR14]\]. One was due to successive lobar intracerebral haematomas in a 19-year old at 30 weeks of gestation, and the second was due to a massive haemorrhage in the intra-peritoneal cavity with multiple AVMs in the gastrointestinal tract.

The most frequent complications were related to PAVMs. Ten women had acute PAVM-related haemothorax \[[@CR15]--[@CR24]\] and of them, 3 had been screened for PAVMs before pregnancy or even been aware of their HHT diagnosis \[[@CR18], [@CR22], [@CR24]\]. Haemoptysis during pregnancy occurred in 4 HHT cases \[[@CR25]--[@CR28]\]. Two were weak and both women were able to give birth to live infants at 37 weeks \[[@CR26], [@CR27]\]; one woman had been diagnosed and treated for PAVMs 5 years previously. Recanalization of the pulmonary AVM sac, necessary partly because of the pregnancy, occurred with subsequent haemoptysis. Despite successful therapeutic re-embolisation of the afferent pulmonary artery, haemoptysis recurred 5 days later \[[@CR28]\]. Three women presented with dyspnoea related to severe hypoxaemia \[[@CR18], [@CR29], [@CR30]\] and early-onset foetal growth restriction resulted in foetal death at 25 weeks' gestation in one case \[[@CR18]\].

Neurological complications were related to PAVMs in 1 case \[[@CR31]\]: this woman with HHT had an ischaemic stroke with hemiparesis in the third trimester of her pregnancy while she was being treated for PAVMs. The patient developed severe pulmonary insufficiency with post-partum haemothorax \[[@CR31]\]. The complications were related to CAVMs and intracranial haemorrhage in 2 cases \[[@CR13], [@CR32]\], resulting in one foetal death.

Complications were related to hepatic AVMs (HAVMs) in 8 case reports \[[@CR33]--[@CR39]\]. There were 6 cases of acute decompensation heart failure due to hepatic involvement during pregnancy. In one case, a pregnant woman with previously unknown HHT was admitted for pre-term labour and cardiac failure. After a caesarean section, congestive signs improved with medical treatment \[[@CR36]\]. In other cases of HHT undiagnosed during pregnancy, congestive heart failure improved spontaneously after delivery \[[@CR34], [@CR35], [@CR37]\]. Three women underwent a post-partum liver transplant. In 1 case, the pregnant woman with known HHT had severe cholangitis and progressive liver dysfunction; delivery was induced in order to allow the liver transplant to be performed \[[@CR40]\]. In 2 other cases, the women had hepatobiliary necrosis diagnosed on the basis of acute abdominal pain \[[@CR38], [@CR39]\]. One woman had digestive bleeding from a perforated gastric ulcer that could not be controlled endoscopically \[[@CR14]\]. Branch retinal artery occlusion was observed in one case \[[@CR41]\].

Discussion {#Sec8}
==========

In the context of pregnancy, severe complications can occur in HHT women, and this literature review indicates that HHT pregnancies are likely to present significant maternal and/or foetal risks. One large study reported that the overall maternal death rate was 1.0% of pregnancies (95% confidence interval \[0.1; 1.9\]) \[[@CR8]\] based on analysis of retrospective and prospective data and on data from the "relatives group", defined as non-HHT women's first degree relatives. Interestingly, all deaths occurred in women not under medical supervision for HHT. Furthermore, 2 case reports indicated a fatal maternal outcome in 2 cases \[[@CR13], [@CR14]\]. This maternal death rate is probably underestimated in cases of women undiagnosed before pregnancy. Severe maternal complications occurred in 2.7 to 6.8% of pregnancies \[[@CR8], [@CR10], [@CR12]\] in the case series and 31 case reports published from 1986 to 2018. This indicates that, in women known to have HHT, and even if the majority of HHT pregnancies are uneventful, specific high-risk pregnancy monitoring is needed. Foetal death is very rare: among the case reports, 3 foetal deaths were reported \[[@CR13], [@CR16], [@CR18]\], secondary to maternal complications, severe hypoxaemia with early-onset growth retardation at 25 weeks' gestation in one case and maternal intracranial haemorrhage in the other case, with maternal death.

Pregnancy has a dramatic effect on the cardiovascular system and many complications in the HHT pregnancies occurred in the second and third trimesters at the time when peripheral resistance is reduced (by 35--40%), as is systemic vascular resistance \[[@CR42]\]. Furthermore, given the physiological demands of utero-placental circulation and the developing foetus, there is an increase in cardiac output, with the biggest increase of up to 45% from baseline occurring during the first trimester. The increase in cardiac output slows late in the second trimester and drops slightly, late in the third trimester. We hypothesized that the complications in HHT patients during pregnancy related to pulmonary, liver and cerebral AVMs are favoured by these vascular changes in an abnormal vascular bed. Moreover, it has been shown by Rizvi et al. that, in patients with pulmonary AVMs - a chronic adapted state - evaluating arterial oxygenation can be falsely reassuring during pregnancy and haemoglobin is a vital determinant of arterial oxygen content that needs to be evaluated \[[@CR43]\].

Screening and treatment of PAVMs before pregnancy is a priority because these are present in 25 to 50% of HHT women and can lead to haemothorax, which was the most frequent complication in the published case series and case reports. Incidence of haemothorax in 2 studies was 2.1% (4/185) (95% confidence interval 0.7--5.6%) \[[@CR12]\], and 1.4% (6/484) (95% confidence interval 0.2--2.5%) \[[@CR8]\] per pregnancy. However, as reported by Shovlin et al. \[[@CR8]\], there was significant improvement in survival in women in whom the diagnosis of HHT or PAVMs had been made before pregnancy; all women in whom the diagnosis had been made previously, and who presented with haemothorax, survived. On the other hand, PAVM bleeds could be observed even in women who had been previously treated with embolotherapy before the pregnancy. Other complications related to PAVMs include haemoptysis, severe hypoxaemia, paradoxical emboli with brain abscess, paradoxical emboli with ischaemic cerebral stroke, paradoxical emboli with ocular ischaemia. Most complications from PAVMs occurred during the second or third trimester, which seems to be related to high cardiac output. In treated or untreated patients, specific clinical monitoring should be proposed, including regular measuring of oxygen saturation, and all patients should be informed of the risk of coughing up blood, which is not a nosebleed, and it should justify an immediate specialised consultation to exclude a PAVM rupture \[[@CR8], [@CR12]\].

Complications related to HAVMs were described in 8 case reports but were rare in case series. We can hypothesize that this difference is related to recruitment bias. The largest series published were from HHT expert centres specialised in pulmonology and internal medicine and not from hepato-gastroenterology or cardiology \[[@CR8], [@CR11], [@CR12]\]. The most common complication of HAVMs in patients with HHT leads to high-output cardiac failure (6 cases \[[@CR12], [@CR34]--[@CR37]\]), followed by hepatobiliary necrosis leading to liver transplant in 2 cases \[[@CR38], [@CR39]\]. Severe liver involvement in HHT is rare in young patients and usually clinically diagnosed through dyspnoea in women after the age of 50 years \[[@CR44]\]. For this reason, complications are rare between 20 and 40 years of age even if cardiac output is higher during pregnancy, but easy to screen by liver Doppler ultrasound \[[@CR45]\].

The risk of complications from cerebral or spinal AVMs was very low in the case series (4 intracranial haemorrhages \[[@CR8], [@CR12]\], no spinal haemorrhage) and case reports (2 intracranial haemorrhages \[[@CR13], [@CR32]\], no spinal haemorrhage). During pregnancy, spontaneous intracranial haemorrhage in all women occurs at a rate of 0.9 to 7.5 per 100,000 deliveries \[[@CR46]\], which is higher than non-pregnant age-matched women. Even if CAVMs are frequent in asymptomatic HHT patients (15--25%) \[[@CR47]\], it has been suggested that the risk of intracranial brain haemorrhage in HHT patients was lower than in sporadic CAVM patients \[[@CR48]\]. This is not true for the risk of rebleeding, with a higher risk of re-rupture \[[@CR49]\]. Screening for CAVMs is highly debated among HHT experts. The most recent HHT guidelines were drawn up in 2006 and concluded that there is no evidence for guiding the management of CAVMs during pregnancy and delivery \[[@CR50]\]. The bleeding risk with CAVMs in HHT has been estimated retrospectively at 0.5% per year \[[@CR48]\], but there are several cases of dramatic haemorrhage. Furthermore, even if the treatment can reduce risks, the prevention procedures have their own complication rate, and treatment techniques have treatment-associated morbidity and mortality \[[@CR51], [@CR52]\]. This was highlighted by the ARUBA trial (A Randomized Trial of Unruptured Brain Arteriovenous Malformations) that found that medical management alone was more effective than interventional therapy \[[@CR51], [@CR53]\]. We did not find any report of spinal AVM bleeding during pregnancy or more particularly at birth after epidural anaesthesia, even if it is a potential risk. Spinal AVMs are rare and have mostly been reported in children \[[@CR54]\].

Finally, HHT can affect pregnancies with intra-uterine growth retardation and intra-uterine foetal death via chronic hypoxaemia, maternal hypovolaemia or maternal death. However, in the published series, miscarriage was observed in 14.4 to 20% during the first trimester \[[@CR9], [@CR11], [@CR12]\], and prematurity in 9.4, 13.8 and 12% \[[@CR9], [@CR11], [@CR12]\]. These figures were not significantly different from those of the control group, nor those found in the general population.

Conclusion {#Sec9}
==========

Improving HHT diagnosis and information via reference centres and general information is an objective, and women should be educated about screening and possible pregnancy-related risks before becoming pregnant. In all cases, even if severe complications are rare, HHT pregnancies are high-risk and need reinforced monitoring from a maternal as well as a foetal point of view.
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